Krystal Biotech, Inc.
KRYS
$188.61
-$0.57-0.30%
| Weiss Ratings | KRYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Reward Grade | C | |||
| Rating Factors | KRYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | KRYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.07 | |||
| Price History | KRYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 2.02% | |||
| 30-Day Total Return | 16.11% | |||
| 60-Day Total Return | 17.27% | |||
| 90-Day Total Return | 3.01% | |||
| Year to Date Total Return | 20.52% | |||
| 1-Year Total Return | 10.09% | |||
| 2-Year Total Return | 152.09% | |||
| 3-Year Total Return | 181.55% | |||
| 5-Year Total Return | 385.73% | |||
| 52-Week High % Change | -13.75% | |||
| 52-Week Low % Change | 33.49% | |||
| Price | KRYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $219.34 | |||
| 52-Week Low Price | $141.72 | |||
| 52-Week Low Price (Date) | Jan 14, 2025 | |||
| 52-Week High Price (Date) | Jul 26, 2024 | |||
| Valuation | KRYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 5.45B | |||
| Enterprise Value | 4.71B | |||
| Price/Earnings (TTM) | 63.14 | |||
| Earnings Per Share (TTM) | 3.00 | |||
| Earnings Per Share Growth | 3,746.21% | |||
| Price/Earnings To Growth | 0.02 | |||
| Price/Sales (TTM) | 19.46 | |||
| Price/Book (Q) | 5.76 | |||
| Enterprise Value/Revenue (TTM) | 16.20 | |||
| Price | $188.61 | |||
| Enterprise Value/EBITDA (TTM) | 44.55 | |||
| Enterprise Value/EBIT | 45.61 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | KRYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 29.88M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | KRYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 412 586 5830 | |||
| Address | 2100 Wharton Street Pittsburgh, PA 15203 | |||
| Website | www.krystalbio.com | |||
| Country | United States | |||
| Year Founded | 2016 | |||
| Profitability | KRYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 35.52% | |||
| Profit Margin | 30.69% | |||
| Management Effectiveness | KRYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 6.88% | |||
| Return on Equity | 10.34% | |||
| Income Statement | KRYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 290.51M | |||
| Total Revenue (TTM) | 290.51M | |||
| Revenue Per Share | $9.72 | |||
| Gross Profit (TTM) | 270.45M | |||
| EBITDA (TTM) | 105.66M | |||
| EBIT (TTM) | 103.19M | |||
| Net Income (TTM) | 89.16M | |||
| Net Income Avl. to Common (TTM) | 89.16M | |||
| Total Revenue Growth (Q YOY) | 116.26% | |||
| Earnings Growth (Q YOY) | 423.23% | |||
| EPS Diluted (TTM) | 3.00 | |||
| EPS Diluted Growth (Q YOY) | 409.41% | |||
| Balance Sheet | KRYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 597.52M | |||
| Cash Per Share (Q) | $20.00 | |||
| Total Current Assets (Q) | 742.05M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 946.38M | |||
| Current Ratio (Q) | 7.275 | |||
| Book Value Per Share (Q) | $32.87 | |||
| Total Assets (Q) | 1.06B | |||
| Total Current Liabilities (Q) | 102.00M | |||
| Total Debt (Q) | 7.26M | |||
| Total Liabilities (Q) | 109.46M | |||
| Total Common Equity (Q) | 946.38M | |||
| Cash Flow | KRYS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -163.44M | |||
| Cash from Financing (TTM) | 27.01M | |||
| Net Change in Cash (TTM) | -13.46M | |||
| Levered Free Cash Flow (TTM) | 92.96M | |||
| Cash from Operations (TTM) | 123.42M | |||
